Geron (GON) AI Stock Analysis

7 Followers

Geron

(Frankfurt:GON)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

RYTELO Revenue GrowthSustained RYTELO demand growth indicates expanding commercial adoption rather than reliance on a single launch milestone. Rising revenue provides a stronger base for operating leverage, supports investment in market access, and improves the durability of Geron’s commercialization strategy.

Negative Factors

Continued Cash BurnPersistent negative operating and free cash flow means the business has not yet become self-funding despite commercial revenue growth. If this burn continues, Geron may have less flexibility for pipeline investment and could remain dependent on its cash resources or future financing.

Geron (GON) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 657.12M
Dividend Yield: ―
Average Volume (3M): 3,522
Price to Earnings (P/E): -14.6
Beta (1Y): 0.79
Revenue Growth: 12.93%
EPS Growth: 41.13%
Country: Germany
Employees: 258
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Geron Business Overview & Revenue Model

Company Description

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3...

Geron Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:8.47%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call was predominantly positive, with four consecutive quarters of RYTELO demand growth, 27% year-over-year revenue growth, reaffirmed revenue guidance, lower operating expenses, a strong cash position, and the start of a European commercial launch. The principal negative was the discontinuation of the IMpactMF trial after it was deemed unlikely to meet its overall survival endpoint, although management stated that no new safety signals changed imetelstat's known safety profile.

Positive Updates

RYTELO Demand and Revenue Growth

RYTELO demand increased 10% quarter-over-quarter in the third quarter, while net product revenue grew 5% sequentially to $60.1 million and increased 27% year-over-year from $47.2 million in Q3 2025.

Negative Updates

IMpactMF Phase III Trial Discontinued

Geron discontinued the Phase III IMpactMF trial evaluating imetelstat in relapsed/refractory myelofibrosis after the independent data monitoring committee determined that the trial was unlikely to meet its primary endpoint of overall survival.

Company Guidance

Geron reiterated 2026 RYTELO net revenue guidance at $220 million to $240 million, expecting to come in at the mid- to high end of the $220 million to $240 million range, and lowered total operating expense guidance from $230 million to $240 million to the range of $220 million to $230 million; for the remainder of 2026, gross to net is expected to be in the low to mid-20s, inventory is expected to remain within the 2% to 4% guidance, and RYTELO is expected to be commercially available in Germany by the end of this year, with plans to follow in 2027. Management said there will be some increases next year as the Europe strategy matures and for the post-marketing commitment in clinical trials, while the remainder of OpEx will be steady.

Geron Risk Analysis

Geron disclosed 67 risk factors in its most recent earnings report. Geron reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Geron Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:GON against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	73Outperform	$826.82M	2.65	73.94%	―	2.18%	165.65%
PBYI	64Neutral	$420.82M	16.97	17.52%	―	9.35%	-37.15%
XNCR	54Neutral	$2.96B	-25.46	-21.29%	―	33.55%	11.51%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KURA	48Neutral	$673.43M	-2.34	-336.24%	―	-23.76%	-33.09%
CTMX	47Neutral	$431.65M	-4.72	-33.97%	―	-87.66%	-210.45%

* Healthcare Sector Average

Performance Comparison

DE:GON and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:GON	Geron Corporation	0.88	-0.18	-16.68%
RIGL	Rigel Pharmaceuticals	44.52	4.64	11.63%
PBYI	Puma Biotechnology	8.08	3.13	63.23%
XNCR	Xencor Inc.	39.97	25.98	185.70%
CTMX	CytomX Therapeutics Inc.	2.13	-1.73	-44.82%
KURA	Kura Oncology	7.73	-2.95	-27.62%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Geron AI Stock Analysis